Ezra Bernstein, MD

Genitourinary Cancers & Politics. Views are my own.

[Ezra Bernstein, MD @Doctor_EZ]

Huge congrats, @DanaFarber is lucky to have you!!

[Nazli Dizman @NazliDizman]

🎉Beyond thrilled to have joined and to be working with the incredible @DrChoueiri et al @DanaFarber!

A very special thank you to @montypal for his tremendous mentorship and support! And many thanks to all the other mentors who have helped me along the way 🙏

😅 Looking back as a PGY-14, it only took two internal medicine residencies, a few research years, and an oncology fellowship to get here. But I enjoyed every bit of the journey and met so many incredible people!!

@UniversiteEge @YaleIMed @UTMDAnderson @cityofhope @IMG_Oncologists @ASCOTECAG @ASCO @DanaFarber_GU @ConquerCancerFd @kureit @kidneycan @KidneyCancer

[Ezra Bernstein, MD @Doctor_EZ]

@VanAllenLab incredible work!

[Eli Van Allen @VanAllenLab]

In our latest, we studied how certain immune cells surround bladder tumors and contribute to chemotherapy resistance, pointing to a surprising potential therapeutic target ...

Congrats @CarvalhoFilipeL @mouwlab et al! @CellPressNews @cellpressblue https://t.co/EcC0AXH32c

[Lung Cancer Europe @LungCancerEu]

‼️ A tumour isn’t necessarily the same all the way through.

Different populations of cancer cells can exist within it and evolve over time, including under the pressure of treatment.

A new Nature Cancer review looks at how understanding and tracking that evolution could lead to better ways to diagnose, monitor and treat cancer.

#LungCancer research has been central to building that understanding. #LCSM

https://t.co/SiV3LbBDLA

[Tom Powles @tompowles1]

We know most bladder cancers express HER-2 protein, which has become useful ADC target. @scocmem shows >90% of patients also express HER 1 and HER 3 (usually concurrently). This is relevant because the IZABRIGHT R3 trial (enrolling) tests a HER1/3 dual target ADC (IzaBren) in UC. New targets =new opportunities/combinations @montypal @DrChoueiri @Annals_Oncology @ESMO_Open

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @US_FDA approves LuPSMA (Pluvicto, @Novartis) in combination with androgen receptor pathway inhibitor (ARPI) in PSMA (+) metastatic hormone-sensitive prostate cancer. Approval based on PSMAddition trial (HR PFS 0.72), immature OS.

[Ezra Bernstein, MD @Doctor_EZ]

@Reuschal He did something right

[Tom Powles @tompowles1]

In this article @Annals_Oncology GLP1 receptor agonists reduce cancer incidence. The focus is on those cancers linked to obesity @AparnaKamatMD . A retrospective study with a large sample size in people looking to lose weight . A detailed case/control type method. 41%⬇️ in cancer with GLP1 injections. It’s not clear if the effects of wt loss or the agonists are having an effect. Validation needed. Great work!!

[Ezra Bernstein, MD @Doctor_EZ]

@Reuschal In medicine, we would call that a bad prognostic factor

[Ezra Bernstein, MD @Doctor_EZ]

@DrKarieRuncie amazing presentation at @kidneycan

Well deserved award for your incredible research and presentation!!!
#kcrs26

[Ezra Bernstein, MD @Doctor_EZ]

We rocked the run!!!! @TayoAdeoyeMD @ja_ocejo

@kidneycan
@DrKarieRuncie @NazliDizman thanks for the support, we couldn’t have done it without you
#kcrs26

[Toni Choueiri, MD @DrChoueiri]

Our #KCRS26 keynote speaker Dr. Craig Thompson @MSKCancerCenter linking obesity, immune metabolism and RCC, with many mentees such as @ZiadBakouny and @mvh_lab

@kidneycan @HHammersMD @arihakimi @montypal @DrRanaMcKay

[Nazli Dizman @NazliDizman]

Excellent Q&A with Dr. @Arie_Belldegrun at #KCRS26 on career decisions, transitions, innovation, strengthening investigator-industry partnerships, and healthcare entrepreneurship.

Kudos to @DrChoueiri and #DrMikeAtkins for a fantastic conversation! 👏 @kidneycan

[Ezra Bernstein, MD @Doctor_EZ]

So apparently Trump card >> red card. In fairness, it should not have been a red card.
#usa #trump #trumpcard #redcard #balogun #belgium #fifa #worldcup

[Toni Choueiri, MD @DrChoueiri]

🚨 Results from #LITESPARK022 (#LS022) are out in @NEJM!

1/This phase III trial evaluated whether adding the HIF-2α inhibitor Belzutifan (BEL) to adjuvant pembrolizumab (PEMBRO) could improve outcomes for patients with resected clear-cell RCC at increased risk for recurrence.

https://t.co/1BLAercj3p
@oncoalert @asco @myESMO

[MJosé Juan @mjuanfi81]

One bladder cancer doesn’t fit all

Histological variants are biologically different:
✅ Early RC remains the standard for most of them.
✅Platinum-etoposide NAC in small-cell UC
✅Molecular profiling is needed

Great review👉👉https://t.co/hxf6zPIYKA

@OncoAlert @IBCG_BladderCA

[Oncology Brothers @OncBrothers]

A few combination options we touched on and have in upfront settings for metastatic RCC:

⭐️ Nivo/Ipi
⭐️ Nivo/Cabo
⭐️ Pembro/Axi
⭐️ Pembro/Len
** Single agent TKIs and Avelumab/Axi have fallen out of favor **

#OncTwitter #KidneyCancer #MedX #gusm

[Oncology Brothers @OncBrothers]

We touched on 6 studies (3 from #ASCO26 and 3 recent @FDAOncology ✅) during our GU Malignancies Conference Highlights w/ @Uromigos

⭐️ #PROTEUS
⭐️ #TALAPRO3
⭐️ #EV302
✅ #POTOMAC
✅ #CAPItello281
✅ #LITESPARK022

#OncTwitter #gusm @OncUpdates